Clearmind says CMND-100 meets primary endpoint in Phase I/IIa AUD trial

• Clearmind Medicine reported April 14, 2026 that CMND-100 met primary endpoint in its FDA-cleared Phase I/IIa trial in patients with moderate to severe alcohol use disorder.
• Results have been presented, with third-cohort data showing drug was well tolerated at highest dose tested so far.
• Trial outcome supported safety profile, with no serious adverse events reported in third cohort.
• Readout supports continued development of CMND-100 as a potential non-hallucinogenic oral treatment option for alcohol use disorder.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-043235), on April 14, 2026, and is solely responsible for the information contained therein.